Clinical Trials in the UK / NCT03424018
Active, not recruiting
Phase 3
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Achondroplasia
Investigational drug(s) / intervention(s)
BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Eligibility
Inclusion Criteria:
* Must have completed Study 111-301
* Female \>= 10 years old or who have begun menses must have a negative pregnancy test at the Baseline Visit and be willing to have additional pregnancy tests during the study
* If sexually active, willing to use a highly effective method of contraception while participating in the study
* Are willing and able to perform all study procedures
* Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, subjects under the age of majority are willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure. Subjects who reach the age of majority in their country while the study is ongoing will be asked to provide their own written consent again upon reaching the legal age of majority.
Exclusion Criteria:
* Permanently discontinued BMN 111 or placebo prior to completion of the 111-301 study
* Have a clinically significant finding or arrhythmia on Baseline ECG that indicates abnormal cardiac function
* Evidence of decreased growth velocity (\<1.5 cm/year) as assessed over a period of at least 6 months or of growth plate closure (proximal tibia, distal femur) through bilateral lower extremity X-rays.
* Require any investigational agent prior to completion of study period
* Current therapy with medications known to alter renal function
* Pregnant or breastfeeding or plan to become pregnant during study
* Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason.
* Have a condition or circumstance that, in the view of the investigator, places the subject at high risk for poor treatment compliance or for not completing the study.
Primary outcome measure(s)
- Change from baselines in mean annualized growth velocity — Through study completion, an average of 1 year
Long term efficacy as measured by change in annualized growth velocity
Trial sites (24)
| Facility | City | Region | Status |
|---|---|---|---|
| Children's Hospital & Research Center Oakland | Oakland | California | |
| Harbor - UCLA Medical Center | Torrance | California | |
| Alfred I. duPont Hospital for Children | Wilmington | Delaware | |
| Emory University | Atlanta | Georgia | |
| Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | |
| Johns Hopkins University | Baltimore | Maryland | |
| University of Missouri | Columbia | Missouri | |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | |
| Baylor College of Medicine | Houston | Texas | |
| Seattle Children's Hospital | Seattle | Washington | |
| Medical College of Wisconsin, Children's Hospital | Milwaukee | Wisconsin | |
| The Children's Hospital at Westmead | Westmead | New South Wales | |
| Murdoch Children's Research Institute | Parkville | Victoria | |
| Otto-von-Gericke Universitaet, Universitaetskinderklinik | Magdeburg | Germany | |
| Universitätsklinikum Münster | Münster | Germany | |
| Osaka University Hospital | Osaka | Japan | |
| Saitama Children's Medical Center | Saitama | Japan | |
| Tokushima University Hospital | Tokushima | Japan | |
| Institut Catala de Traumatologica I Medicina de l'Esport | Barcelona | Spain | |
| Hospital Sant Joan de Deu | Barcelona | Spain | |
| Hospital Universitario Virgen de la Victoria | Málaga | Spain | |
| Acibadem University School of Medicine | Istanbul | Turkey (Türkiye) | |
| Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital | London | United Kingdom | |
| Sheffield Children's NHS Foundation Trust | Sheffield | United Kingdom |
More BioMarin Pharmaceutical trials in the UK
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
Active, not recruiting
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
Enrolling by invitation
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
Active, not recruiting
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
Active, not recruiting
AAV Gene Therapy Study for Subjects with PKU
Active, not recruiting
Other trials for the same condition
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03424018 on ClinicalTrials.gov ↗ ← All trials in the UK